Career history of Michael D. Laufert
Former positions of Michael D. Laufert
| Companies | Position | Start | End |
|---|---|---|---|
Guilford Pharmaceuticals, Inc.
 Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Corporate Officer/Principal | - | - |
| GCP Fund III Corp. | Corporate Officer/Principal | - | - |
| PFIZER, INC. | Corporate Officer/Principal | - | - |
Training of Michael D. Laufert
| The Johns Hopkins University | Masters Business Admin |
| Mount Saint Mary's University | Undergraduate Degree |
| Georgetown University | Graduate Degree |
Statistics
International
| United States | 7 |
Operational
| Corporate Officer/Principal | 3 |
| Masters Business Admin | 1 |
| Graduate Degree | 1 |
Sectoral
| Consumer Services | 4 |
| Health Technology | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PFIZER, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
| GCP Fund III Corp. |
- Stock Market
- Insiders
- Michael D. Laufert
- Experience
